Savara (SVRA) Tax Provisions (2017 - 2018)
Savara (SVRA) reported Tax Provisions of $2.5 million for Q4 2018, up 24900.0% year-over-year from N/an in Q4 2017, and up 2372.73% quarter-over-quarter from -$110000.0 in Q3 2018.
Savara (SVRA) Tax Provisions (2017 - 2018) Analysis & Trends
Savara (SVRA) has 2 years of Tax Provisions data on file, last reported at $2.5 million in Q4 2018.
- Tax Provisions for Q4 2018 came in at $2.5 million, up 24900.0% year-over-year; the trailing twelve-month figure through Dec 2018 was -$2.4 million (down 200.0% YoY), and the FY2018 annual result was -$7.1 million, down 766.95% from the prior year.
- Tax Provisions climbed to $2.5 million in Q4 2018 per SVRA's latest filing, from -$110000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $2.5 million in Q4 2018 and troughed at -$4.6 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 216,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 2.50 Mn |
| Sep 30, 2018 | -110,000.00 |
| Jun 30, 2018 | -277,000.00 |
| Mar 31, 2018 | -4.56 Mn |
| Dec 31, 2017 | 10,000.00 |
| Sep 30, 2017 | -117,000.00 |
| Jun 30, 2017 | -470,000.00 |
| Mar 31, 2017 | -237,000.00 |